BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gruticibart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Gruticibart\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07498517-920@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290202
DTEND;VALUE=DATE:20290203
SUMMARY:Gruticibart: Phase 2 readout est. (NCT07498517)
DESCRIPTION:Gruticibart\, phase 2.\nStudy: Safety and Efficacy of a Single 
 Dose of Gruticibart to Prevent CRT\nEstimated primary completion: 2 Februa
 ry 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/gruticibart#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0749
 8517
URL:https://assetmemo.bio/drug/gruticibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
